Agnese Comelli

Dr. Agnese Comelli

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2020 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
APAndrea Pilotto
Andrea Pilotto
SOSilvia Odolini
Silvia Odolini
SMS Stefano Masciocchi
S Stefano Masciocchi
ACAgnese Comelli
Agnese Comelli
IVIrene Volonghi
Irene Volonghi
APAlessandro Padovani
Alessandro Padovani

21 February 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
NDNunzia Decembrino
Nunzia Decembrino
KPK. Perruccio
K. Perruccio
MZM. Zecca
M. Zecca
ACA. Colombini
A. Colombini
ECE. Calore
E. Calore
Simone CesaroSimone Cesaro
Simone Cesaro
We analyzed the use of isavuconazole (ISA) as treatment or prophylaxis for invasive fungal disease (IFD) in children with hemato-oncologic diseases. A multicentric retrospective analysis was performed among centers belonging to the Italian Association for Pediatric Hematology and Oncology (AIEOP). Pharmacokinetic (PK) monitoring was applied by a high-performance liquid chromatography-tandem mass spectrometry (HLPC-MS/MS) assay.

22 March 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
ACAgnese Comelli
Agnese Comelli
GVGiulia Viero
Giulia Viero
GBGreta Bettini
Greta Bettini
ANAlessandro Nobili
Alessandro Nobili
MTMauro Tettamanti
Mauro Tettamanti
ABAlessandra Bandera
Alessandra Bandera
Objective: Our knowledge on the long-term consequences of COVID-19 is still scarce despite the clinical relevance of persisting syndrome. The aim of this study was to analyze patient-reported outcomes, including assessment by specific questionnaires of health impairment and symptoms.Methods: This is a prospective, observational and multicenter cohort study coordinated by Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico di Milano and Istituto di Ricerche Farmacologiche Mario Negri IRCCS including eight hospitals located in North and Central Italy. A telephone interview to assess rehospitalization, access to health care resources, general health status subjective evaluation, and symptoms was performed at 12 months after the discharge in patients admitted to hospital because of COVID-19 from February 2020 to the end of May 2020.Results: Among the 776 patients discharged alive, 44 (5.7%) died, 456 subjects (58.8%) completed the questionnaire and 276 (35.6%) were not reachable or refused to join the telephone interview. The mean age of the study population was 59.4 years (SD 14.1), 69.8% of individuals needed oxygen support during hospitalization and 10.4% were admitted to ICU. Overall, 91.7% of participants reported at least one symptom/sequela at 12 months. Exertional dyspnea (71.7%), fatigue (54.6%), and gastrointestinal symptoms (32.8%) were the most reported ones. Health issues after discharge including hospitalization or access to emergency room were described by 19.4% of subjects. Female and presence of comorbidities were independent predictors of whealth impairment and presence of ≥2 symptoms/sequelae after 12 months from hospitalization for COVID-19.Conclusions: Patient-reported symptoms and sequelae, principally dyspnea and fatigue, are found in most individuals even 12 months from COVID-19 hospitalization. Long-term follow-up based on patient-centered outcome can contribute to plan tailored interventions.

1 May 2020 in Future Microbiology
Verified
Journal Article
Closed access
NRNiccolo Riccardi
Niccolo Riccardi
AGAndrea Giacomelli
Andrea Giacomelli
DCDiana Canetti
Diana Canetti
ACAgnese Comelli
Agnese Comelli
EIEnrica Intini
Enrica Intini
ABAntonio Di Biagio
Antonio Di Biagio
Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such ...

16 October 2019 in Journal of Travel Medicine
Verified
Journal Article
Closed access
ACAgnese Comelli
Agnese Comelli
NRNiccolò Riccardi
Niccolò Riccardi
DCDiana Canetti
Diana Canetti
MSMichele Spinicci
Michele Spinicci
GCGiovanni Cenderello
Giovanni Cenderello
GGGiovanni Gaiera
Giovanni Gaiera
Background: Barriers to access to care, different diagnostic strategies and low awareness remain challenging issues in the fight against schistosomiasis. Our study aims to examine management of schistosomiasis in migrants attending large tertiary hospitals in Italy, in order to call for a comprehensive approach. Methods: A retrospective review of schistosomiasis cases was carried out between January 1, 2016, and December 31, 2017, in five large Infectious Disease Centers in Italy. We included all patients diagnosed with schistosomiasis. We differentiated among (i) asymptomatic patients diagnosed by serology either as healthy ‘migrant evaluation’ or as ‘late evaluation’ in patients followed because of a different infection and (ii) patients tested because of a suggestive clinical presentation. Patients characteristics and clinical data were recorded. Results: One hundred forty-nine patients were included, 137 (91.9%) were male, the median age was 26 years and 70% of them came from Sub-Saharan Africa. Thirty-eight asymptomatic patients (25.5%) were diagnosed by serology [15, (10.1%) among ‘migrant evaluation’ and 23 (15.4%) among ‘late evaluation’ group], and 111 (74.5%) presented with signs/symptoms. The median diagnostic delay from arrival in Italy was 31 months: 110 for asymptomatic group and 16 months for symptomatic patients. Among the 111 symptomatic patients, 41 individuals were already followed in our clinics, and they never underwent screening before appearance of evident disease. Among patients with positive serology who were tested by microscopy, 32/86 (37.2%) had confirmed diagnosis. Forty-five (37.8%) patients presented radiologic abnormalities. Praziquantel was the treatment of choice (70.1% for 3 days and 29.9% in a single-day dose), and 77 (51.7%) were lost to follow-up. Conclusions: In our centers, a high proportion of patients were tested late after arrival, and most of them presented with clinical apparent disease. Well-defined strategies and implementation of recent guidelines are needed to improve early diagnosis and to overcome heterogeneity of practice.

12 June 2017 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
NDN Decembrino
N Decembrino
ACAgnese Comelli
Agnese Comelli
FGF Genco
F Genco
AVA Vitullo
A Vitullo
SRS Recupero
S Recupero
VMV Meroni
V Meroni